Skip to search boxSkip to navigationSkip to main content

Versican promotes tumor progression, metastasis and predicts poor prognosis in renal carcinoma

  • Yozo Mitsui(corresponding author)
    ,
  • Hiroaki Shiina
    ,
  • Taku Kato
    ,
  • Shigekatsu Maekawa
    ,
  • Yutaka Hashimoto
    ,
  • Marisa Shiina
*Corresponding author for this work
  • Shimane University
    ,
  • University of California at San Francisco
    ,
  • VA Medical Center
    ,
  • The University of Osaka
    ,
  • Toho University
Scholary Output:
Contribution to journal
Article
Research
Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

The proteoglycan versican (VCAN) promotes tumor progression and enhances metastasis in several cancers; however, its role in clear cell renal cell carcinoma (ccRCC) remains unknown. Recent evidence suggests that VCAN is an important target of chromosomal 5q gain, one of the most prevalent genetic abnormalities in ccRCC. Thus, we investigated whether VCAN expression is associated with the pathogenesis of ccRCC. VCAN expression was analyzed using three RCC and normal kidney cell lines as well as a clinical cohort of 84 matched ccRCC and normal renal tissues. Functional analyses on growth and progression properties were performed using VCAN-depleted ccRCC cells. Microarray expression profiling was employed to investigate the target genes and biologic pathways involved in VCAN-mediated ccRCC carcinogenesis. ccRCC had elevated VCAN expression in comparison with normal kidney in both cell lines and clinical specimens. The elevated expression of VCAN was significantly correlated with metastasis (P < 0.001) and worse 5-year overall survival after radical nephrectomy (P - 0.014). In vitro, VCAN knockdown significantly decreased cell proliferation and increased apoptosis in Caki-2 and 786-O cells, and this was associated with alteration of several TNF signaling-related genes such as TNFa, BID, and BAK. Furthermore, VCAN depletion markedly decreased cell migration and invasion which correlated with reduction of MMP7 and CXCR4. These results demonstrate that VCAN promotes ccRCC tumorigenesis and metastasis and thus is an attractive target for novel diagnostic, prognostic, and therapeutic strategies.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Research
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 884-895 (12 pages)

Journal (Volume, Issue Number)

Molecular Cancer Research (Volume 15, Issue 7)

Publication milestones

  • Published - 07/2017

Publication status

Published - 07/2017

ISSN

1541-7786

Publication IDs

  • Scopus: 85021810372
  • PubMed: 28242813

Publication metrics

Metrics

SciVal
FWCI
1.87
SciVal
Author count
20
SciVal
citations
29
SciVal
Paper percentile
93
SciVal
Top percentile
10
Fractional count
1
Fractional count
0.05
Fractional count
19
Fractional count
0.95
Fractional count
1
Fractional count
1
Scopus
citations

PlumX, opens in new tab

Captures
50
Citation count
73
Mentions
1

Funding Details

This study was supported by Department of Veterans Affairs Merit Review and National Cancer Institute (#R01CA199694) grants.
FundersFunding number
NCI
R01CA199694
VA
-